A selective 5-hydroxytryptamine 2C agonist developed to treat obesity as an appetite suppressant. The extra weight loss compared to placebo weight reducing diet is about 2kg in a 100kg patient at 3 years, that is 4kg in total.
Oral 10mg bd
(Based on clinical trial exclusions)
- Heart failure (EF <20%)
- Severe valvular heart disease
- Severe renal failure
- Severe hepatic failure
Cautions and Interactions
- Increased risk of severe hypoglycaemia in diabetics on oral hypoglycaemics.
- May aggrevate pre existing depression
Might work in schizophrenia. Fifteen times more selective at 5-HT(2C) than 5-HT(2A) and 100 times more selective at 5-HT(2C) than 5-HT(2B). In rats at high doses it induces tumours. Three year follow up suggests good cardiovascular safety. It probably has a side effect profile that helps with stress incontinence but no issues with urinary retention are reported.